ProQuad

RSS

measles, mumps, rubella and varicella vaccine (live)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for ProQuad. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for ProQuad.

This EPAR was last updated on 06/12/2018

Authorisation details

Product details
Name
ProQuad
Agency product number
EMEA/H/C/000622
Active substance
virus, live attenuated, measles, virus, live attenuated, mumps, virus, live attenuated, rubella, virus, live attenuated, varicella
International non-proprietary name (INN) or common name
measles, mumps, rubella and varicella vaccine (live)
Therapeutic area (MeSH)
  • Chickenpox
  • Rubella
  • Measles
  • Mumps
  • Immunization
Anatomical therapeutic chemical (ATC) code
J07BD54
Publication details
Marketing-authorisation holder
MSD VACCINS
Revision
24
Date of issue of marketing authorisation valid throughout the European Union
05/04/2006
Contact address
162 avenue Jean Jaurès
69007 Lyon
France

Product information

18/10/2018 ProQuad - EMEA/H/C/000622 - WS/1392

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age.

ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating